You might worry that a stronger drug means harsher side effects
What started as diabetes drugs, liraglutide (Victoza, 2010) and semaglutide (Ozempic, 2017), has become the fastest-growing drug class in pharmaceutical history
64 (s1), S379S395
While the foundations of a healthy lifestyle will always begin with diet and exercise, and bariatric procedures can be the right choice for patients with the chronic health issues associated with severe obesity, GLP-1 receptor agonists provide another safe, effective, and measured approach
The defining characteristic of a habit catalyst is that it expands the conditions under which habits can take hold
Availability depends on regulatory review, approximately 10 to 12 months for FDA review, and production scale-up post-approval